drugset
drugset / Trial / NCT06105528

A Phase 1a Study of PMN310 In Healthy Volunteers

NCT06105528 ↗

Phase 1 Completed 40 enrolled ProMis Neurosciences, Inc
RandomizedSequentialDouble-blindTreatment

Summary

This first in human Phase 1a clinical trial will evaluate the safety, tolerability, and pharmacokinetics of a single IV infusion of PMN310 in healthy volunteers.

Timeline

Start
2023-11-18
Primary completion
2024-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PMN310 Monoclonal antibody 175 mg Intravenous
Subject PMN310 Monoclonal antibody 350 mg Intravenous
Subject PMN310 Monoclonal antibody 700 mg Intravenous
Subject PMN310 Monoclonal antibody 1400 mg Intravenous
Subject PMN310 Monoclonal antibody 2800 mg Intravenous

Indications

No indication recorded.